Gustav U.
- Country
- Sweden
- Department
- Department of oncology
Research Overview
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- Phase Ib/II Study of Momelotinib Combined with Anti‑PD‑1 Therapy (Nivolumab or Pembrolizumab) in Unresectable Stage III/IV Cutaneous Melanoma
- Percutaneous Hepatic Perfusion with Melphalan Plus Ipilimumab and Nivolumab Versus Ipilimumab and Nivolumab in Uveal Melanoma Liver Metastases
Data & Insights
Has run more than one trial at 9 of 225 partner sites.
Specializations
Melanoma Research
This investigator specializes in the treatment of uveal melanoma and cutaneous malignant melanoma, with particular focus on advanced stages of the disease involving liver metastases.
- Uveal Melanoma Liver Metastases
- High-risk Malignant Melanoma
- Stage IIb-c, III and IV Melanoma
The investigator explores innovative therapeutic approaches combining surgical intervention with immunotherapy strategies.
Immunotherapy Applications
The researcher focuses on advancing immunotherapy treatments through various therapeutic combinations and optimization of treatment duration.
- Combination Immunotherapy
- Adjuvant Immunotherapy
- Novel Treatment Duration Protocols
Research includes evaluation of immunotherapy agents such as ipilimumab, nivolumab, and pembrolizumab.
Advanced Cancer Treatment
The investigator studies innovative therapeutic approaches for advanced tumors, including specialized hepatic treatment methods.
- Percutaneous Hepatic Perfusion
- Advanced Tumor Management
- Survival Outcome Assessment
Research encompasses both localized treatment strategies and systemic therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.